Abstract: The present invention relates to substituted imidazo-pyridinones and imidazo-pyridazinones of general formula wherein Y and R1 to R4 are defined as in claim 1, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Abstract: A predetermined business task of a composite application can be fulfilled. The composite application can include a set of components. The composite application is instantiated by a template means and a predefined collaborative context module controls the interaction of the set of components during the runtime of the composite application. A set of components fulfilling individual services on individual different server systems is leveraged by the composite application. During the instantiation of the composite application from a template, the referenced components (as types) are instantiated leading to runtime instances of these components. The interaction of the different components is controlled on individual different server systems utilizing a primary context module.

Abstract: The invention relates to new purine derivatives of general formula wherein R1 to R4 are defined as in the claims, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV), the preparation thereof, the use thereof for the prevention or treatment of diseases or conditions associated with an increased DPP-IV activity or capable of being prevented or alleviated by reducing the DPP-IV activity, particularly type I or type II diabetes mellitus, the pharmaceutical compositions containing a compound of general formula (I) or a physiologically acceptable salt thereof as well as processes for the preparation thereof.

Abstract: The present invention relates to substituted imidazo-pyridinones and imidazo-pyridazinones of general formula wherein Y and R1 to R4 are defined as in claim 1, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Abstract: The present invention relates to substituted xanthines of general formula the tautomers, the stereoisomers, the mixtures thereof, the prodrugs thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Abstract: The present invention relates to the field of network portals and in particular to a method and system for exchanging data between components of one or more composite applications implemented on a portal server, wherein the components are programmed independently from each other. An embodiment of the invention includes: automatically intercepting I/O data being input or output respectively to or from the components or a browser; extracting data objects from the I/O data; determining for a source component, which of the data objects match input requirements of which other potential target components; selecting matching data objects for a matching target component; and transferring the matching data objects to the matching target component.

Abstract: Compounds of formula (I) wherein R1 to R4 are defined as in the claims, or the prodrugs or salts thereof, particularly the physiologically acceptable salts thereof, pharmaceutical compositions containing these compounds, and methods of treating type I and type II diabetes mellitus, arthritis, obesity, allograft transplantation, or calcitonin-induced osteoporosis using these compounds.

Abstract: Embodiments of systems and methods provide deployable cellular telecommunication base stations capable of sending, receiving, and extending telephone calls in areas where commercial cellular communications are unavailable. The deployable base station can send and receive cellular telephone calls via cellular communication transceivers, and relay such calls to a distant teleport via a satellite communication link. The deployable base station includes routers for encoding voice calls in voice-over IP data format and for routing calls via the satellite communication link. The deployable base station may also include land mobile radio (LMR) communication interoperability circuits to enable LMR communications to be relayed to a distant teleport. At the teleport, received communications can be routed via a public switched telephone network to an intended receiver to enable telephone communications with the global commercial network from areas lacking commercial cellular communications.

Abstract: Disclosed are substituted xanthines of general formula wherein R1 to R4 are defined hereinbelow, the tautomers, the stereoisomers, the mixtures thereof, the prodrugs thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Abstract: Compounds of formula (I) wherein R1 is a phenylcarbonylmethyl group wherein the phenyl moiety is substituted, and R2 to R4 are defined as in the claims, or the prodrugs or salts thereof, particularly the physiologically acceptable salts thereof, pharmaceutical compositions containing these compounds, and methods of treating type I and type II diabetes mellitus, arthritis, obesity, allograft transplantation and calcitonin-induced osteoporosis using these compounds.

Abstract: The present invention relates to the field of portal programming and in particular to a method and respective system for managing community control information in a portal environment. In order provide a method and system which facilitates the management of community membership information required for portal composite applications, it is proposed to generate and store a “user-to-role mapping” data item (55) in a respective storage structure and use that as re-usable control information intended to be easily re-usable for further or even many composite applications, which are managed including the use of that storage structure.

Abstract: Disclosed are substituted xanthines of general formula wherein R1 to R4 are defined hereinbelow, the tautomers, the stereoisomers, the mixtures thereof, the prodrugs thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Abstract: The invention relates to a method of providing a composite portal application for a portal server application environment. In accordance with an embodiment of the invention, the method comprises: providing application components in machine readable code for forming the portal application; providing an application assembly descriptor in machine readable code, wherein the application assembly descriptor comprises meta-data, wherein the meta-data specifies how the application components have to be assembled to provide the composite portal application on the portal server application environment; providing a set of functions; using the functions of the set of functions as points of variability in the meta-data, wherein the functions are adapted to be evaluated by the portal server application environment.

Abstract: An apparatus for preparing a finely divided meal or flour product includes at least one pair of corrugated rolls, a first drive mechanism for rotating a first roll in a first direction at a first speed, and a second drive mechanism for counter-rotating a second roll in a second direction at a second slower speed. Each roll is provided with Twin City Chunk corrugations set in an outer surface of the rolls in a spiral pattern of about 1.5 inches per lineal foot. The difference in rotational speeds of the first and second rolls provides a reduction ratio of about 2:5.1. Finely divided meal or flour products and methods for producing the products using the disclosed apparatus are also provided.

Abstract: The present invention relates to substituted xanthines of general formula wherein R1 to R3 are defined as in claims 1 to 16, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Abstract: The present invention relates to substituted xanthines of general formula wherein R1 to R3 are defined as in claims 1 to 16, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Abstract: This invention relates to a separation process comprising (i) introducing a vapor phase mixture into a condensing apparatus, said vapor phase mixture comprising at least one desirable component and at least one undesirable component; (ii) controlling the temperature in the condensing apparatus utilizing a heat-transfer gas; and (iii) operating the condensing apparatus at a temperature and a pressure sufficient to selectively condense at least a portion of said vapor phase mixture and thereby yield a recovered content containing said at least one desirable component. The separation process is useful in semiconductor applications such as recovery of unreacted organometallic compound precursors in chemical vapor deposition or atomic layer deposition processes.

Abstract: The present invention relates to substituted xanthines of general formula wherein R1 to R3 are defined as in claims 1 to 16, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Abstract: A modular fiber optic light line unit has a housing in which distal portions of one or more fiber optic bundles fan out such that termini of the fibers are arrayed in a continuous fiber row. The proximal ends of the bundles are held in respective sleeves, and light source modules are removably attached over the sleeves to generate light that is incident on the proximal end of the bundle. The light source modules are removably installed by pushing on, without requiring tools. The light source modules have a canister housing containing a solid-state light source, e.g., five watts. Heat management is achieved using fins on the modular housing. Different color wavelength light sources can be employed, and the fibers from the various bundles can be interleaved.

Abstract: Illustrative apparatuses and methods for electrostatic discharge protection are described in which the frequency of a voltage received at a first circuit node is filtered to generate a filtered voltage, one or more control signals are generated having either a first voltage or a second voltage depending upon the value of the filtered voltage, and the first circuit node is selectively connected with a second circuit node depending upon the value of the one or more control signals.